Differential cellular effects of old and new oral anticoagulants: Consequences to the genesis and progression of atherosclerosis

Thrombosis and Haemostasis

Volumn 112, Issue 5, 2014, Pages 909-917

  Schurgers, Leon J ^a   Spronk, Henri M H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Arterial thrombosis; Arteriogenesis; Atherosclerosis; Atherothrombosis; Vitamin Kdependent factors

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN DERIVATIVE; PROTEINASE ACTIVATED RECEPTOR; PROTHROMBIN; THROMBIN INHIBITOR; ANTITHROMBIN; PROTEINASE INHIBITOR; VITAMIN K GROUP;

ANGIOGENESIS; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL CALCIFICATION; CELL FUNCTION; CELL MIGRATION; CLINICAL EVALUATION; DRUG MECHANISM; FIBRIN FORMATION; FIBROSIS; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; PATHOPHYSIOLOGY; RISK ASSESSMENT; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BLEEDING; CALCINOSIS; CHEMICALLY INDUCED; CLASSIFICATION; COMPLICATION; DISEASE COURSE; DISEASE MODEL; DRUG MONITORING; ENZYME ACTIVATION; PHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BLOOD COAGULATION FACTORS; CALCINOSIS; COUMARINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG MONITORING; ENZYME ACTIVATION; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PROTEINASE-ACTIVATED; STROKE; THROMBOSIS; VITAMIN K;

EID: 84908553711     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-03-0268     Document Type: Article

References (84)

1. Schofield FW. A brief account of a disease in cattle simulating hemorrhagic septicemia due to feeding sweet clover. Can Vet Rec 1922; 3: 74-79.
2. Campbell M. Haemorrhagic disease in cattle. J Biol Chem 1941; 18: 21-33.
3. Link K. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107.
4. Dam H. The antihemorrhagic vitamin of the chick: occurrence and chemical nature. Nature 1935; 135: 652-653.
5. Stenflo J, Ferlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974; 71: 2730-2733.
6. Versteeg HH, Heemskerk JWM, Levi M, et al. New fundamentals in hemostasis. Physiol Rev 2013; 93: 327-358.
7. Burnier J, Borowski M, Furie B, et al. Gamma-carboxyglutamic acid. Mol Cell Biochem 1981; 39: 191-207.
8. Esmon C, Sadowski J, Suttie J. A new carboxylation reaction. The vitamin K-dependent incorporation of H-14-CO3-into prothrombin. J Biol Chem 1975; 250: 4744-4748.
9. Matschiner JT, Bell RG, Amelotti JM, et al. Isolation and characterization of a new metabolite of phylloquinone in the rat. Biochim Biophys Acta 1970; 201: 309-315.
10. Li T, Chang C, Jin D, et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-544.
11. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-541.
12. Shapiro SS. Treating thrombosis in the 21st century. N Engl J Med 2003; 349: 1762-1764.
13. Levi M, Eerenberg ES, Kampuisen PW. Anticoagulants. Old and new. Hamostaseologie 2011; 31: 229-235.
14. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-2311.
15. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; pp. 257S-298S.
16. Holmes MV, Hunt BJ, Shearer MJ. The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev 2012; 26: 1-14.
17. Chatrou MLL, Winckers K, Hackeng TM, et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev 2012; 26: 155-166.
18. Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med 2013; 19: 217-226.
19. Corral-Rodríguez MA, Macedo-Ribeiro S, Pereira PJB, et al. Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications. J Med Chem 2010; 53: 3847-3861.
20. Markwardt F. Historical perspective of the development of thrombin inhibitors. Pathophysiol Haemost Thromb 2002; 32 (Suppl 3): 15-22.
21. Nutt EM, Jain D, Lenny AB, et al. Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 1991; 285: 37-44.
22. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
23. Wasmer K, Eckardt L. Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace 2011; 13: 1368-1374.
24. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
25. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
26. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
27. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.
28. Borissoff JI, Spronk HMH, Cate Ten H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
29. Sevigny LM, Austin KM, Zhang P, et al. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler Thromb Vasc Biol 2011; 31: e100-106.
30. Shi X, Gangadharan B, Brass LF, et al. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004; 2: 395-402.
31. Lin H, Trejo J. Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits arrestin-mediated endosomal signalling. J Biol Chem 2013; 288: 11203-11215.
32. Arachiche A, Mumaw MM, la Fuente de M, et al. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by thrombin. J Biol Chem 2013; 288: 32553-32562.
33. Borensztajn K, Spek CA. Blood coagulation factor Xa as an emerging drug target. Expert Opin Ther Targets 2011; 15: 341-349.
34. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signalling in physiology and disease. Trends Mol Med 2008; 14: 429-440.
35. Zhou Q, Bea F, Preusch M, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; 2011: 432080.
36. Kalz J, Cate Ten H, Spronk HMH. Thrombin generation and atherosclerosis. J Thromb Thrombolysis 2014; 37: 45-55.
37. Hamilton JR, Cornelissen I, Mountford JK, et al. Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/-mice. Atherosclerosis 2009; 205: 427-432.
38. Patterson C, Stouffer GA, Madamanchi N, et al. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res 2001; 88: 987-997.
39. Wilcox JN, Noguchi S, Casanova J. Extrahepatic synthesis of factor VII in human atherosclerotic vessels. Arterioscler Thromb Vasc Biol 2003; 23: 136-141.
40. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
41. Borissoff JI, Heeneman S, Kilinç E, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122: 821-830.
42. Borissoff JI, Otten JJT, Heeneman S, et al. Genetic and Pharmacological Modifications of Thrombin Formation in Apolipoprotein E-deficient Mice Determine Atherosclerosis Severity and Atherothrombosis Onset in a Neutrophil-Dependent Manner. PLoS one 2013; 8: e55784.
43. Khallou-Laschet J, Caligiuri G, Tupin E, et al. Role of the intrinsic coagulation pathway in atherogenesis assessed in hemophilic apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: e123-126.
44. Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood 2007; 110: 4261-4267.
45. Westrick RJ, Bodary PF, Xu Z, et al. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 2001; 103: 3044-3046.
46. Tilley RE, Pedersen B, Pawlinski R, et al. Atherosclerosis in mice is not affected by a reduction in tissue factor expression. Arterioscler Thromb Vasc Biol 2006; 26: 555-562.
47. Loeffen R, Spronk HMH, Cate ten H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost 2012; 10: 1207-1216.
48. de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44: 106-113.
49. Houbballah R, LaMuraglia GM. Clotting problems: diagnosis and management of underlying coagulopathies. Semin Vasc Surg 2010; 23: 221-227.
50. Foley CJ, Nichols L, Jeong K, et al. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 8: 208-211.
51. Tuinenburg A, Rutten A, Kavousi M, et al. Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 799-804.
52. Zwiers M, Lefrandt JD, Mulder DJ, et al. Coronary artery calcification score and carotid intima-media thickness in patients with hemophilia. J Thromb Haemost 2012; 10: 23-29.
53. Bilora F, Zanon E, Petrobelli F, et al. Does hemophilia protect against atherosclerosis? A case-control study. Clin Appl Thromb Hemost 2006; 12: 193-198.
54. Srámek A, Reiber JH, Gerrits WB, et al. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 2001; 104: 762-767.
55. Narins CR, Zarba W, Moss AJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004; 164: 440-446.
56. Lowe GDO, Sweetnam PM, Yarnell JWG, et al. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004; 24: 1957-1962.
57. Salomaa V, Stinson V, Kark JD, et al. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 91: 284-290.
58. Smith FB, Rumley A, Lee AJ, et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758-763.
59. Tataru MC, Heinrich J, Junker R, et al. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 1999; 20: 1493-1502.
60. Páramo JA, Orbe J, Beloqui O, et al. Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 2004; 35: 1085-1089.
61. Kienast J, Thompson SG, Raskino C, et al. Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993; 70: 550-553.
62. Henareh L, Jogestrand T, Agewall S. Prothrombin fragment 1 + 2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction. Thromb Res 2009; 124: 526-530.
63. Di Tullio MR, Homma S, Jin Z, et al. Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study. J Am Coll Cardiol 2008; 52: 855-861.
64. Borissoff JI, Joosen IA, Versteylen MO, et al. Accelerated In Vivo Thrombin Formation Independently Predicts the Presence and Severity of CT Angiographic Coronary Atherosclerosis. JACC Cardiovasc Imaging 2012; 5: 1201-1210.
65. Price P, Faus S, Williamson M. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407.
66. Schurgers LJ, Joosen IA, Laufer EM, et al. Vitamin k-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS one 2012; 7: e43229.
67. Krüger T, Oelenberg S, Kaesler N, et al. Warfarin induces cardiovascular damage in mice. Arterioscler Thromb Vasc Biol 2013; 33: 2618-2624.
68. Schurgers LJ, Aebert H, Vermeer C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004; 104: 3231-3232.
69. Weijs B, Blaauw Y, Rennenberg RJMW, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32: 2555-2562.
70. Shanahan CM, Crouthamel MH, Kapustin A, et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
71. Nadra I, Mason J, Philippidis P, et al. Proinflammatory Activation of Macrophages by Basic Calcium Phosphate Crystals via Protein Kinase C and MAP Kinase Pathways: A Vicious Cycle of Inflammation and Arterial Calcification? Circ Res 2005; 96: 1248-1256.
72. Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-alpha promotes In vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636-2642.
73. Pazár B, Ea H-K, Narayan S, et al. Basic Calcium Phosphate Crystals Induce Monocyte/Macrophage IL-1{beta} Secretion through the NLRP3 Inflammasome In Vitro. J Immunol 2011; 186: 2495-2502.
74. Ewence AE, Bootman M, Roderick HL, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103: e28-34.
75. Kapustin AN, Davies JD, Reynolds JL, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011; 109: e1-12.
76. Van Der Meijden PEJ, Van Schilfgaarde M, van Oerle R, et al. Platelet-and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-1362.
77. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-1698.
78. Christersson C, Oldgren J, Wallentin L, et al. Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med 2011; 270: 215-223.
79. Bea F, Kreuzer J, Preusch M, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 2787-2792.
80. Lee I-O, Kratz MT, Schirmer SH, et al. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 2012; 343: 253-257.
81. Ragosta M, Gimple LW, Gertz SD, et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1994; 89: 1262-1271.
82. Liska DJ, Suttie JW. Location of gamma-carboxyglutamyl residues in partially carboxylated prothrombin preparations. Biochemistry 1988; 27: 8636-8641.
83. Bae J-S, Yang L, Rezaie AR. Factor X/Xa elicits protective signalling responses in endothelial cells directly via PAR-2 and indirectly via endothelial protein C receptor-dependent recruitment of PAR-1. J Biol Chem 2010; 285: 34803-34812.
84. Spronk HMH, de Jong AM, Crijns HJ, et al. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res 2014; 101: 344-351.